Reports for APOTEX INC
Company Name APOTEX INC |
||
|---|---|---|
Totals |
||
Shortage reports |
3367 |
|
| Actual shortage: | 219 (7%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 341 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2024-03-15 | 2024-04-19 | 222464 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2020-06-24 | 2020-08-17 | 118778 |
| APO-SUMATRIPTAN | 50MG | TABLET | Resolved | 2023-03-16 | 2023-03-30 | 187235 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2023-02-09 | 2023-02-23 | 184109 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2021-05-07 | 2021-06-14 | 138978 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2021-06-04 | 2021-08-13 | 140439 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2021-07-16 | 2021-08-16 | 142690 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2021-08-27 | 2021-09-14 | 144669 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2021-11-12 | 2021-11-29 | 149170 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2022-01-21 | 2022-02-28 | 153288 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2022-02-18 | 2022-04-08 | 155324 |
| APO-TADALAFIL | 2.5MG | TABLET | Resolved | 2022-03-11 | 2022-04-01 | 156555 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2022-03-25 | 2022-04-29 | 157332 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2017-10-23 | 2017-11-29 | 26646 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2017-11-21 | 2018-01-08 | 29949 |
| APO-TADALAFIL | 10MG | TABLET | Resolved | 2018-01-17 | 2018-05-15 | 36347 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2018-02-01 | 2018-05-15 | 37983 |
| APO-TADALAFIL | 2.5MG | TABLET | Resolved | 2017-07-11 | 2017-12-07 | 15409 |
| APO-TADALAFIL | 20MG | TABLET | Resolved | 2017-08-24 | 2017-10-11 | 20245 |
| APO-TADALAFIL | 5MG | TABLET | Resolved | 2019-03-05 | 2019-04-26 | 77896 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |